| Literature DB >> 34946052 |
Ye-Ji Jang1, Hee-Min Gwon1, Woo-Soo Jeong1, Soo-Hwan Yeo1, So-Young Kim1.
Abstract
Weissella cibaria is one of the bacteria in charge of the initial fermentation of kimchi and has beneficial effects such as immune-modulating, antagonistic, and antioxidant activities. In our study, we aimed to estimate the safety of W. cibaria JW15 for the use of probiotics according to international standards based on phenotypic (antibiotic resistance, hemolysis, and toxic metabolite production) and genotypic analysis (virulence genes including antibiotic resistance genes). The results of the safety assessment on W. cibaria JW15 were as follows; (1) antibiotic resistance genes (ARGs) (kanamycin and vancomycin etc.) were intrinsic characteristics; (2) There were no acquired virulence genes including Cytolysin (cylA), aggregation substance (asa1), Hyaluronidase (hyl), and Gelatinase (gelE); (3) this strain also lacked β-hemolysis and the production of toxic metabolites (D-lactate and bile salt deconjugation). Consequently, W. cibaria JW15 is expected to be applied as a functional food ingredient in the food market.Entities:
Keywords: ARGs; Weissella cibaria; safety; toxic metabolite; virulence gene
Year: 2021 PMID: 34946052 PMCID: PMC8704421 DOI: 10.3390/microorganisms9122450
Source DB: PubMed Journal: Microorganisms ISSN: 2076-2607
Primer and gene sequences used in this study.
| Anti | Target Genes | Sequences (5′-3′) | Tm | Amplicon Size (bp) | |
|---|---|---|---|---|---|
| F | R | ||||
| Streptomycin | ATCCTTCGGCGCGATTTTG | GCAGCGCAATGACATTCTTG | 53 | 282 | |
| ATGGAATTATTCCCACCTGA | TCAAAACCCCTATTAAAGCC | 53 | 565 | ||
| ATCGTCAAGGGATTGAAACC | GGATCGTAGAACATATTGGC | 55 | 509 | ||
| Tetracycline | TCGATAGGAACAGCAGTA | CAGCAGATCCTACTCCTT | 51 | 169 | |
| TTATGGTGGTTGTAGCTAGAAA | AAAGGGTTAGAAACTCTTGAAA | 52 | 348 | ||
| TTAGGTGAAGGGTTAGGTCC | GCAAACTCATTCCAGAAGCA | 55 | 697 | ||
| Kanamycin | GCCGATGTGGATTGCGAAAA | GCTTGATCCCCAGTAAGTCA | 57 | 292 | |
| GGGCGCGTCATGGAGGAGTT | TATCGCGACCTGAAAGCGGC | 61 | 329 | ||
| Clindamycin | GGTGGCTGGGGGGTAGATGTATTAACTGG | GCTTCTTTTGAAATACATGGTATTTTTCGATC | 59 | 323 | |
| CCTACCTATTGTTTGTGGAA | ATAACGTTACTCTCCTATTTC | 52 | 925 | ||
|
| |||||
| JW15-1_1_00598 | MLKKLGLTAGALAIAIGGTVWFVQNRDAQTATASGELRVVTTNSILEDMVEQVGGDDVSVYSIVKRGTDPHEYEPKTA | ||||
| JW15-1_1_00853 | MAIEKERVDVLAVQQGLFTSREQAKRAIMAGEILGENEQRMDKAGEKIPVTTELHLKGAPMPYVSRGGFKLEKALEVF | ||||
Antibiotic resistance profiles and minimum inhibitory concentration (MIC) values of bacterial strains used in this study.
| Strains | Microbiological Cut-Off Values (mg/L) of Antibiotics | Ref. | ||||||||
|---|---|---|---|---|---|---|---|---|---|---|
| AM | CL | CM | EM | GM | KM | SM | TC | VA | ||
|
| 2 | 4 | 1 | 1 | 16 | 16 | 64 | 8 | N/R | (EFSA a, 2012) |
|
| 0.100 ± 0.000 | 2.300 ± 1.100 | 0.040 ± 0.030 | 0.700 ± 0.400 | 4.500 ± 2.100 | >256 | 56.000 ± 11.300 | 1.800 ± 0.400 | >256 | In this study |
|
| 0.056 ± 0.008 | 2.000 ± 0.000 | 1.000 ± 0.000 | 0.750 ± 0.250 | 6.000 ± 2.000 | >256 | 96.000 ± 0.000 | 1.750 ± 0.250 | >256 | |
|
| 0.095 ± 0.031 | 1.750 ± 0.250 | 0.044 ± 0.021 | 0.875 ± 0.125 | 20.000 ± 4.000 | >256 | 96.000 ± 0.000 | 1.750 ± 0.250 | >256 | |
|
| 4 | 4 | 1 | 1 | 16 | 64 | 32 | 8 | N/R | (EFSA, 2012) |
|
| 0.285 ± 0.095 | 1.250 ± 0.250 | 0.315 ± 0.185 | 0.235 ± 0.145 | 96.000 ± 0.000 | >256 | 96.000 ± 0.000 | 0.470 ± 0.280 | >256 | In this study |
a European Food Safety Authority (EFSA) 2012; AM, ampicillin; CL, chloramphenicol; CM, clindamycin; EM, erythromycin; GM, gentamicin; KM, kanamycin; SM, streptomycin; TC, tetracycline; VA, vancomycin; N/R, not required.
Detection for antibiotics resistance genes (ARGs).
| Antibiotic | Target Gene | Ref. | ||||||||
|---|---|---|---|---|---|---|---|---|---|---|
| Chromosome | Plasmid | Chromosome | Plasmid | Chromosome | Plasmid | Chromosome | Plasmid | |||
| SM | [ | − | − | − | − | − | − | − | − | |
| [ | − | − | − | − | − | − | − | − | ||
| [ | − | − | − | − | − | − | − | − | ||
| TC | [ | − | − | − | − | − | − | − | − | |
| [ | − | − | − | − | − | − | − | − | ||
| [ | − | − | − | − | − | − | − | − | ||
| KM | [ | − | − | − | − | − | − | − | − | |
| [ | − | − | − | − | − | − | − | − | ||
| CM | [ | − | − | − | − | − | − | − | − | |
| [ | − | − | − | − | − | − | − | − | ||
−: not detected; SM, streptomycin; TC, tetracycline; KM, kanamycin; CM, clindamycin.
Figure 1A circular map of the chromosome of JW15 strain. The map was drawn by applying Contig 1’s annotation result. From outside to the center: coding sequences (CDS) on forward strand (colored by COG categories of the right side), CDS on reverse strand (colored by COG categories of the right side.), tRNA, rRNA, GC content, and GC skew (+: green, −: violet). The complete genome contained 2,472,214 bp with G+C content of 45.09%.
Bioinformatic analysis for the presence of putative virulence factor-related genes in the genomes of strain JW15.
| Class | Gene | ||
|---|---|---|---|
| Contig 1 | Contig 2, 3, 4 | ||
| Enterotoxin |
| − | − |
| Leucotoxin |
| − | − |
| Cytolysin |
| − | − |
| Cytotoxin K |
| − | − |
| Hemolysin |
| − | − |
| Gelatinase |
| − | − |
| Amino acid decarboxylase |
| − | − |
|
| − | − | |
|
| − | − | |
|
| − | − | |
| Hyaluronidase |
| − | − |
| Aggregation substance |
| − | − |
| Enterococcal surface protein |
| − | − |
| Endocarditis antigen |
| − | − |
| Adhesion of collagen |
| − | − |
| Cereulide |
| − | − |
| Sex pheromones |
| − | − |
| Serine protease |
| − | − |
| Transposon-related genes |
| − | − |
| BLASTX results against VFDB was filtered based on followed thresholds; | |||
| Coverage 70% | |||
| Percent identity 50% | |||
Homology analysis of two genes presumed to be VF-genes in the genome of W. cibaria JW 15 strain.
| Locus Tag | VFDB Reference | NCBI-Nr Database Reference | Uniprot Database Reference | |||
|---|---|---|---|---|---|---|
| Id(%) | Gene Name | Id(%) | Gene Name | Id(%) | Gene Name | |
| JW15-1_1_00598 | 57.4 | (efaA) endocarditis specific antigen | 100 | zinc ABC transporter substrate-binding protein | 98.7 | SsaB protein ( |
| 51.1 | Metal ABC transporter substrate-binding lipoprotein ( | |||||
| JW15-1_1_00853 | 53.1 | putative RNA methyltransferase [Hemolysin (CVF417)] | 100 | TlyA family RNA methyltransferase | 99.6 | Cell division protein FtsJ ( |
| 86.4 | 23S rRNA (Cytidine1920-2′-O)/16S rRNA (Cytidine1409-2′-O)-methyltransferase ( | |||||
Figure 2Hemolytic activity of W. cibaria strains and LGG. Complete lysis of blood cells was observed, with clear zones around B. cereus KACC 10004 as positive control.
Enzymatic profiles and assay of toxic metabolic production.
| Enzymatic Profiles | JW15 | LGG | LMG 21843 | LMG 17699 |
|---|---|---|---|---|
| Alkaline phosphatase | − | − | − | − |
| Esterase (C4) | − | + | − | − |
| Esterase lipase (C8) | − | + | − | − |
| Lipase (C14) | − | − | − | − |
| Leucine arylamidase | + | + | + | + |
| Valine arylamidase | − | + | − | − |
| Cystine arylamidase | − | + | − | − |
| Trypsin | − | − | − | − |
| α-chymotrypsin | − | + | − | − |
| Acid phosphatase | + | + | + | + |
| Naphthol-AS-BI- | + | + | + | + |
| α-galactosidase | − | − | − | − |
| β-galactosidase | − | + | − | + |
| β-glucuronidase | − | − | − | − |
| α-glucosidase | − | + | − | − |
| β-glucosidase | − | + | − | + |
| acetyl glucosaminidase | − | − | − | − |
| α-mannosidase | − | − | − | − |
| α-fucosidase | − | + | − | − |
|
| ||||
| Hemolysis (beta-) | − | − | − | − |
| D-lactate (nmol/μL) | 0.010 ± 0.006 | 0.000 ± 0.000 | 0.019 ± 0.011 | 0.015 ± 0.007 |
| Bile salt deconjugation | − | − | − | − |
+: positive, −: negative.
Mutagenic activity in bacterial strains TA98, TA100, TA1535, TA1537, and WP2uvrA treated with W. cibaria JW15, with (+S9) or without (−S9) metabolic activation.
| Dose of | Number of Revertant Colonies per Plate | ||||
|---|---|---|---|---|---|
| TA98 | TA100 | TA1535 | TA1537 | WP2uvrA | |
|
| |||||
| Negative control a | 20.7 ± 0.9 | 103.7 ± 4.2 | 14.8 ± 0.7 | 8.7 ± 0.5 | 41.2 ± 12.5 |
| 313 | 22.3 ± 0.5 | 106.7 ± 6.1 | 13.3 ± 1.4 | 8.7 ± 2.4 | 42.7 ± 12.3 |
| 625 | 21.8 ± 0.2 | 102.3 ± 2.4 | 15.3 ± 0.5 | 8.3 ± 1.4 | 43.5 ± 12.5 |
| 1250 | 19.5 ± 1.6 | 106.3 ± 5.2 | 13.8 ± 1.6 | 9.5 ± 2.6 | 41 ± 13.2 |
| 2500 | 21.3 ± 1.4 | 101.7 ± 3.3 | 15.5 ± 0.2 | 9.7 ± 0.9 | 40.7 ± 14.1 |
| 5000 | 18.8 ± 1.2 | 105.3 ± 7.5 | 13.8 ± 0.2 | 8.7 ± 1.4 | 40.2 ± 12.5 |
| Positive control b | 566.5 ± 18.1 | 621.2 ± 35.6 | 451.5 ± 0.7 | 440.5 ± 18.1 | 227.5 ± 5.9 |
|
| |||||
| Negative control a | 32 ± 0.5 | 112.5 ± 10.6 | 14.2 ± 0.2 | 17 ± 4.2 | 36.3 ± 5.2 |
| 313 | 31 ± 0.5 | 114.7 ± 10.4 | 13.3 ± 0 | 16 ± 4.7 | 35.7 ± 7.1 |
| 625 | 31.7 ± 1.9 | 113.5 ± 13.4 | 14 ± 0.9 | 16.2 ± 5.4 | 36.5 ± 5.9 |
| 1250 | 30.2 ± 0.2 | 111.3 ± 9.4 | 15.5 ± 0.2 | 17 ± 6.6 | 34.8 ± 6.8 |
| 2500 | 32.3 ± 0.9 | 114 ± 10.8 | 15.5 ± 2.1 | 16 ± 6.1 | 36.7 ± 5.7 |
| 5000 | 32.7 ± 0.5 | 110.3 ± 9 | 13.7 ± 0 | 17.3 ± 6.6 | 34.3 ± 6.6 |
| Positive control c | 333.7 ± 46.2 | 667.8 ± 0.2 | 149.3 ± 14.6 | 158.8 ± 17.2 | 454.3 ± 31.1 |
a Nomal saline injection; b positive control without S9 for TA98: 2-Nitrofluorene (2-NF), 5.0 μg/plate; for TA100 and TA1535: Sodiumazide (SA), 1.5μg/plate; for TA1537: 9-Aminoacridine (9-AA), 80.0 μg/plate; for WP2uvrA: 4-Nitroquinoline N-oxide (4-NQO), 0.3 μg/plate; c Positive control with S9: 2-Aminoanthracene (2-AA) for TA98, 1.0 μg/plate; TA100, 2.0 μg/plate; TA1535 and TA1537, 3.0 μg/plate; WP2uvrA, 10.0 μg/plate; S.D.: standard deviation.